Carregant...

A Phase I Trial of Enzastaurin in Patients with Recurrent Gliomas

PURPOSE: Enzastaurin is a selective inhibitor of protein kinase C β. Prior phase I studies did not show increased drug exposures with escalating once daily administration. Limits from gastrointestinal absorption may be overcome by twice daily dosing, potentially improving antitumor effects. EXPERIME...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Kreisl, Teri N., Kim, Lyndon, Moore, Kraig, Duic, Paul, Kotliarova, Svetlana, Walling, Jennifer, Musib, Luna, Thornton, Donald, Albert, Paul S., Fine, Howard A.
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7227612/
https://ncbi.nlm.nih.gov/pubmed/19417015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-3071
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!